Sequence

Garagiste Festival Returns to LA June 22nd with 40 Wineries and a Bounty of Under-the-Radar Grapes

Retrieved on: 
Giovedì, Maggio 9, 2024
Sequence, Olive, Civic, The Dirt, Sale, Wine Country, Wine, Dirt, Diamond, Cal Poly, Cabernet Sauvignon, Weeping Angel, Early access, Research, The Press Democrat, Chardonnay, PASO, Los Angeles Times, The Garagiste Festivals, Viticulture

"Once again, we are bringing the best of Wine Country to Los Angeles with a scope of wineries and grape varieties that would take months, or years, of in-person research to find -- if you could find them at all," said Garagiste Festival Co-founder Doug Minnick. "At Garagiste, we have done the research for you. With our long history as the home of the micro-winery movement, these wineries now seek us out to get their wines to our audience. Our winemakers love to personally pour their wines for you - not only their artisan takes on fan-favorite wines like Cabernet Sauvignon, Pinot Noir, and Chardonnay - but also the widest array of grapes varieties and styles you will find anywhere. And this is exactly what continues to make the Garagiste Festival such a popular and unique event."

Key Points: 
  • With our long history as the home of the micro-winery movement, these wineries now seek us out to get their wines to our audience.
  • And this is exactly what continues to make the Garagiste Festival such a popular and unique event."
  • Among the over 40 winemakers pouring at The Garagiste Festival: Urban Exposure 2024 are:
    Tickets are very limited for the Garagiste Festivals and always sell out.
  • For more information and full Garagiste Festival: Urban Exposure schedule details, go to: https://www.garagistefestival.com/upcoming-events

Ethernet and VoIP Test Solution for High-Speed Network Monitoring and Analytics

Retrieved on: 
Mercoledì, Maggio 8, 2024
Sequence, Transfer, QOS, N10, Internet Protocol version 4, LAN, KPI, IP, RTP, SCTP, Filter, GTP, TCP, VXLAN, GRE, IPv6, Class, Computer, Voice over IP, Gigabit Ethernet, N13, Interior, N12, HD, Inner–outer directions, Data-rate units, Wireless, Quality of service, Mobile phone

With PacketScan™ HD, network engineers and cyber security professionals can accurately assess their network performance, identify bottlenecks, troubleshoot infrastructure and applications, and investigate security incidents.

Key Points: 
  • With PacketScan™ HD, network engineers and cyber security professionals can accurately assess their network performance, identify bottlenecks, troubleshoot infrastructure and applications, and investigate security incidents.
  • Vijay Kulkarni, CEO of GL Communications, states, “GL’s PacketScan™ HD is an Ethernet monitoring device designed for high-density network analysis.
  • Equipped with specialized network interface cards, ample storage capacity, and advanced protocol analysis software, it captures and decodes all Voice over IP (VoIP) and Wireless protocols over IP.
  • TCP Analytics is an optional feature with the PacketScan™ HD - Network Monitoring Appliance.

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI

Retrieved on: 
Giovedì, Maggio 9, 2024
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Sequence, Brain, Drug design, Protein, AI, Dyno, Business development, RNA, AAV, Engineering, DNA, Patient, Eye, NVIDIA, Drug discovery, Therapy, Algorithm, Medical imaging

Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.

Key Points: 
  • Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.
  • Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI.
  • Dyno believes transformative sequence design capabilities can be brought within reach using its extensive proprietary datasets and the scale NVIDIA’s compute platform enables.
  • “NVIDIA’s collaboration with Dyno will optimize and scale high-performance biological sequence design, helping to dramatically accelerate the pace of drug discovery and development.”
    All patients can potentially benefit from the ability to design therapies based on biological sequences.

Scholastic Education Solutions Announces New Collection, Our Stories Decodables, for Early Reading Instruction

Retrieved on: 
Mercoledì, Maggio 8, 2024
Sequence, Science, Education, Texas A&M University, Learning, Learning sciences, Book, Clark Atlanta University, Literacy, Collection, Scholastic, Literature, Jamaican Patois, Multimedia, Howard University, Student, Spelman College

NEW YORK, May 8, 2024 /PRNewswire/ -- Today, Scholastic, the global children's publishing, education, and media company, announced the pre-order of Our Stories Decodables, a collection of 24 culturally affirming decodable books designed for young readers. The collection, which will be available for classrooms in September, supports children in grades K-2 who are learning the foundations of sounds and spelling, as well as students who need additional support through grades 3-5. To ensure the collection represents diverse children and their families, the titles were written by authors representing various backgrounds including first-time writers responding to a call for entries from Historically Black Colleges and Universities (HBCUs).

Key Points: 
  • Our Stories Decodables aims to bridge this gap for teachers and students, particularly for early readers as they begin their literacy journeys.
  • In addition, the collection provides 18 decodable student texts, six review books, a teacher's guide, oral reading rubric, and downloadable take-home books.
  • Through these texts and resources, students are able to practice sounds and spellings, recognize themselves in the stories, and increase confidence in their reading capabilities.
  • Educators can use the collection as a supplement to a comprehensive phonics program and aligns with all Scholastic Ready4Reading™ modules.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.

Green Plains Reports First Quarter 2024 Financial Results

Retrieved on: 
Venerdì, Maggio 3, 2024
Alternative Energy, Energy, Agriculture, Natural Resources, Sequence, Glucose, Negotiation, Gasoline, Yeast, Aviation biofuel, Food safety, Enzyme, Mergers and acquisitions, Partner, Policy, Natural gas, Depreciation, Partnership, Biopolymer, Transport, Carbon, Ethanol, Plant, Obion, Tennessee, JV, Eye, Corn oil, Acquisition, Food, Marketing, Becker

Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.

Key Points: 
  • Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.
  • Revenues were $597.2 million for the first quarter of 2024 compared with $832.9 million for the same period last year.
  • The consolidated ethanol crush margin was ($9.3) million for the first quarter of 2024, compared with ($12.5) million for the same period in 2023.
  • Intersegment activities between the partnership and Green Plains Trade associated with terminal services transacted with the agribusiness and energy services segment will continue to be eliminated on a consolidated level.

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Retrieved on: 
Martedì, Aprile 30, 2024
Sequence, Cancer, AUC, WTS, AI, Prognosis, RNA, MD, Partnership, Doctor of Philosophy, Research, DNA, Health information management, Data, Patient, Record, RWD, Health, WES, Biomarker, Medicine, Quality of life, COTA, Medical imaging

IRVING, Texas and NEW YORK, April 30, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics company used by the world's leading pharmaceutical companies, today announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care. 

Key Points: 
  • The combination of the breadth and depth of Caris' genomic, transcriptomic, proteomic and imaging data and COTA's high-quality curated clinical data that captures the treatment journeys and outcomes of cancer patients will result in a broad real-world, multi-modal data offering, at scale, to power the next wave of cancer therapeutics.
  • "Caris' partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development.
  • Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage for every viable sample.
  • "By combining COTA's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life," said C.K.

WW International, Inc. Announces First Quarter 2024 Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Sequence, Nature, Average cost, Depreciation, Hand, Publishing, Webcast, Strategic planning, Forecasting, Wind, Digital, Tax, Operating cost, Acquisition, GAAP, Reinsurance

End of Period Subscribers in Q1 2024 were down 0.4% versus the prior year period.

Key Points: 
  • End of Period Subscribers in Q1 2024 were down 0.4% versus the prior year period.
  • Interest Rate Hedges: The Company’s interest rate swaps in effect as of the end of the first quarter of fiscal 2024 terminated on March 31, 2024.
  • During the conference call, Sima Sistani, Chief Executive Officer, and Heather Stark, Chief Financial Officer, will discuss the first quarter of fiscal 2024 results and answer questions from the investment community.
  • In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results.

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Retrieved on: 
Martedì, Aprile 23, 2024
Sequence, Small RNA, RNA editing, Potency, Durability, Health, ...Continued, RNA, MD, Doctor of Philosophy, Weight loss, IND, CNS, Obesity, Oligonucleotide, GSK, Patient, Medicinal chemistry, MBA, Liu Wei, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities.

Key Points: 
  • As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation.
  • GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs.
  • Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM™ platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas.
  • Beyond these programs, our collaboration is focusing on all Wave modalities, including RNA editing.

Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights

Retrieved on: 
Giovedì, Aprile 25, 2024
Oncology, Data Management, Health, Technology, Genetics, Artificial Intelligence, Biotechnology, Cancer, Sequence, Genetic testing, Disease, Patient, Genome, Diagnosis, Whole genome sequencing, Genetic counseling

Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.

Key Points: 
  • Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively.
  • The clinical use of whole genome sequencing has relatively been limited due to cost and technology barriers.
  • “This milestone solidifies our position as the whole-genome precision health leader.”
    Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.
  • The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone.